Allarity Therapeutics, Inc. (NASDAQ:ALLR) Short Interest Update

Allarity Therapeutics, Inc. (NASDAQ:ALLR) was the recipient of a significant decline in short interest in the month of June. As of June 15th, there was short interest totalling 1,040,000 shares, a decline of 11.1% from the May 31st total of 1,170,000 shares. Based on an average daily volume of 4,870,000 shares, the days-to-cover ratio is presently 0.2 days. Approximately 4.1% of the shares of the company are sold short.

Allarity Therapeutics Trading Up 3.9 %

NASDAQ:ALLR opened at $0.21 on Monday. The firm’s fifty day moving average price is $0.71 and its two-hundred day moving average price is $5.37. Allarity Therapeutics has a one year low of $0.19 and a one year high of $269.80.

Allarity Therapeutics (NASDAQ:ALLR) last released its quarterly earnings results on Tuesday, May 14th. The company reported ($22.14) earnings per share for the quarter. On average, sell-side analysts forecast that Allarity Therapeutics will post -2.6 EPS for the current fiscal year.

Hedge Funds Weigh In On Allarity Therapeutics

A hedge fund recently bought a new stake in Allarity Therapeutics stock. Armistice Capital LLC acquired a new stake in Allarity Therapeutics, Inc. (NASDAQ:ALLR) during the third quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 261,000 shares of the company’s stock, valued at approximately $195,000. Armistice Capital LLC owned approximately 9.56% of Allarity Therapeutics at the end of the most recent reporting period. 11.53% of the stock is currently owned by institutional investors.

About Allarity Therapeutics

Allarity Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme.